Ginkgo Bioworks vs Mesa Laboratories
Mesa Laboratories reported revenue of $249 million in fiscal 2026, 1.5 times Ginkgo Bioworks' $170 million in fiscal 2025. Ginkgo Bioworks' revenue fell 25.1% in its latest year, and Mesa Laboratories' grew 3.4%. Ginkgo Bioworks had an operating margin of -185.3%, against 7.4% at Mesa Laboratories. Free cash flow was −$179 million at Ginkgo Bioworks and $40 million at Mesa Laboratories. Their fiscal years end in different months (December 31 and March 31), so the periods don't line up exactly.
Side by side
| Ginkgo Bioworks | Mesa Laboratories | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2026, Mar 31, 2026 |
| Revenue | $170M | $249M |
| Revenue growth | −25.1% | 3.4% |
| Revenue growth a year, last 5 years | 17.3% | 13.2% |
| Gross margin | — | 63.5% |
| Operating margin | −185.3% | 7.4% |
| Net margin | −183.8% | 2.7% |
| Free cash flow | −$179M | $40M |
| Free cash flow margin | −105.0% | 15.9% |
| Return on capital | — | 4.8% |
| Net debt to EBITDA | — | 1.0x |
| Dividends and buybacks | $0M | $4M |
| Change in diluted share count | 6.9% | 2.7% |
| Last close | $9.61 | $139.01 |
| P/E at the last close | — | 120.9× |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 8 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Ginkgo BioworksMesa Laboratories
Operating margin
Percent of revenue
Ginkgo BioworksMesa Laboratories
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Ginkgo BioworksMesa Laboratories
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Ginkgo Bioworks and Mesa Laboratories pages.